EP4 receptor antagonist 7, identified by its CAS number 3035217-40-1, is a chemical compound that functions as an antagonist for the EP4 receptor, which is a subtype of the prostaglandin E receptor. This receptor plays a significant role in various physiological processes, including inflammation, pain perception, and immune responses. The antagonist properties of EP4 receptor antagonist 7 suggest that it can inhibit the action of prostaglandin E2 at the EP4 receptor, potentially leading to therapeutic effects in conditions characterized by excessive inflammation or pain. The compound is typically characterized by its specific molecular structure, which includes functional groups that facilitate its interaction with the receptor. Additionally, it may exhibit properties such as solubility in organic solvents, stability under certain conditions, and a defined pharmacokinetic profile. Research into EP4 receptor antagonists like this compound is ongoing, with potential applications in treating diseases such as arthritis, cancer, and other inflammatory disorders.

EP4 antagonist 14 is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM in a reporter assay using HEK293 cells expressing the human receptor.1 It inhibits PGE2-induced β-arrestin recruitment in the same cells (IC50 = 0.9 nM). EP4 antagonist 14 (10 µM) decreases PGE2-induced expression of mRNA encoding Il-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. In vivo, EP4 antagonist 14 (30 mg/kg per day), in combination with an anti-PD-1 antibody, inhibits tumor growth and increases infiltration of CD8+ T cells into tumors in a CT26 murine colon cancer model.WARNING This product is not for human or veterinary use.

EP4 receptor antagonist 7

3035217-40-1: EP4 receptor antagonist 7, identified by its CAS number 3035217-40-1, is a chemical compound that functions as an antagonist for the EP4 receptor, which is a subtype of the prostaglandin E receptor. This receptor plays a significant role in various physiological processes, including inflammation, pain perception, and immune responses. The antagonist properties of EP4 receptor antagonist 7 suggest that it can inhibit the action of prostaglandin E2 at the EP4 receptor, potentially leading to therapeutic effects in conditions characterized by excessive inflammation or pain. The compound is typically characterized by its specific molecular structure, which includes functional groups that facilitate its interaction with the receptor. Additionally, it may exhibit properties such as solubility in organic solvents, stability under certain conditions, and a defined pharmacokinetic profile. Research into EP4 receptor antagonists like this compound is ongoing, with potential applications in treating diseases such as arthritis, cancer, and other inflammatory disorders.

<p>EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4, with an IC50 of 1.1 nM. This compound inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 of 0.9 nM. In RAW 264.7 macrophages, it reduces the expression of PGE2-induced IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C motif) ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase 1 (Arg1) mRNA. In the CT26 mouse colon cancer model, EP4 receptor antagonist 7, combined with an anti-PD-1 antibody, inhibits tumor growth and enhances CD8+ T cell infiltration into the tumor.</p>

CAS 3035217-40-1

EP4 receptor antagonist 7

EP4 receptor antagonist 7

Ref: TM-T204782